stars 1 stars 2 stars 3

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma's online communities are open to the public. Anything posted to our social networks may be seen and read by everyone. We cannot be responsible for views expressed other than our own. By posting on Amryt Pharma's social media pages, you grant us the right to use or reproduce your content. We welcome questions and commentary, including constructive feedback and differing opinions, but please remember to be both relevant and respectful with what you post. We do not tolerate harassment, abuse, or threats to others. We reserve the right to remove any posts that don’t adhere to our guidelines and to block anyone who violates them repeatedly. Learn more about our community guidelines here: https://amrytpharma.com/social-media-guidelines/

View Top Employees from Amryt Pharma

Amryt Pharma Questions

The Amryt Pharma annual revenue was $58 million in 2024.

Shaun Stapleton is the Vice President Regulatory Affairs of Amryt Pharma.

252 people are employed at Amryt Pharma.

The NAICS codes for Amryt Pharma are [2111, 621, 62151, 21, 211, 6215, 21111, 211111, 62].

The SIC codes for Amryt Pharma are [28, 283].

Top Amryt Pharma Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users